Novo Nordisk, the leading global health care company, announced the appointment of Hassan Fahmi as the new General Manager for the company's operations in Egypt effective July 2017. Fahmi has more than 20 years of experience across business development, marketing and communications. Fahmi has held several managerial positions at Novo Nordisk prior to his latest appointment including Business Development Manager, and Marketing and MAPA Director, where he was responsible for the entire diabetes and bio-pharm portfolios, achieving both market share growth and increased sales. Fahmi has a proven track record of brand-building and leadership, coupled with diverse experience of nearly 25 years in Egypt and the Gulf region that were key to his appointment as General Manager and ability to lead the company's operations successfully in Egypt. Fahmi said I am proud to be leading a company that creates life changing medications such as Tresiba® and Victoza®. Tresiba® is a once-daily basal insulin injection allowing flexibility in day-to-day dosing time, providing ultra-long diabetes treatment beyond 42 hours, therefore, it is recommended for people with diabetes who are fasting during the month of Ramadan, and those who may miss their insulin dose due to the change of daily lifestyle during fasting. It provides glycemic control with a lower risk of nocturnal hypoglycemia, while Victoza® helps patients maintain normal blood sugar levels with a once-daily injection that can be taken at any time of day, irrespective of meals with reduced risk of hypoglycaemia. Furthermore, Victoza® can help patients achieve weight loss, by increasing satiety and delaying gastric empting, and thus reducing caloric intake. While it also reduces cardiovascular risks. All these medications have several benefits in achieving a better quality of life" As a part of its commitment to Egyptian patients, Novo Nordisk has launched numerous initiatives in recent years including the opening of Novo care centers across 16 governorates to raise diabetes awareness among people with the disease and the community. Additionally, Novo Nordisk, in cooperation with Ministry of Health, opened two centers of excellence in Om El Masreyin Hospital in Giza and in Ismailia, providing healthcare services to people with diabetes, in addition to specialized doctors for the treatment of diabetes-related complications free of charge, including ophthalmologists, diabetic feet specialists, cardiologists, and neurologists. The centers will also accommodate medical labs for necessary tests.
